Physician profile
Mary Tyson
NPI 1780669218
$16,572.47
in general payments reported to CMS, 2019-2025
15 companies · $2,797 in 2025
The $2,797 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,509 · 2020: $829 · 2021: $1,564 · 2022: $3,186 · 2023: $3,345 · 2024: $3,341 · 2025: $2,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,189 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,189.21 |
| Education | $294.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,230.62 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $2,829.40 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $2,117.23 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,372.15 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,332.13 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,264.35 | 2021-2025 | Vraylar, Ubrelvy |
| Lundbeck LLC | $1,103.47 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $811.94 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $801.39 | 2019-2022 | |
| Indivior INC. | $412.61 | 2021-2023 | Perseris |
| Allergan, INC. | $325.08 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $321.07 | 2019-2025 | Fanapt |
| Axsome Therapeutics, INC. | $304.27 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $302.53 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $44.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.